Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) said on Monday that Selinexor has received orphan drug designation from the European Medicines Agency (EMA) for chronic lymphocytic leukemia (CLL) and
small lymphocytic lymphoma (SLL), including Richter's Transformation, and for multiple myeloma.
M2 PHARMA-June 26, 2017-Verastem Provides Long-Term Data for Duvelisib in Patients with Follicular or
Small Lymphocytic LymphomaThe NDAs for zanubrutinib as a potential treatment for patients with R/R MCL and for patients with R/R chronic lymphocytic leukemia or
small lymphocytic lymphoma were accepted by the NMPA in August and October, respectively.
BeiGene announced the first patient was dosed in a global Phase 3 clinical trial of its investigational BTK inhibitor zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or
small lymphocytic lymphoma. The global Phase 3 open-label trial is expected to enroll approximately 400 patients with relapsed/refractory CLL or SLL across approximately 150 study centers in the U.S., China, Europe, Australia and New Zealand.
M2 PHARMA-November 16, 2015-AbbVie submits sNDA to the US FDA for IMBRUVICA (ibrutinib) combination data for chronic lymphocytic leukemia or
small lymphocytic lymphoma